NCT03932643View on ClinicalTrials.gov

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

October 31, 2026

Study Completion Date

August 31, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

ONC-201

"ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER